Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupHead and Neck OncologyradiotherapyDiseaseSalivary Gland TumorSubgroupAndrogen receptor positiveHER2+ICD10C08.-MeSHSalivary Gland NeoplasmsSequencePERT840/TRAS8, Salivary Gland Tumor, C1 (PID1701) -|- PERT420/TRAS6, C2+ (PID1702)TRAS8/DOCE70, Salivary Gland Tumor, C1 (PID1697) -|- C2+ (PID1698) -|- Maint. (PID1711)ChemotherapyChemo-substanceAbirateroneBicalutamideCisplatinCyclophosphamideDocetaxelDoxorubicinLeuprorelinPaclitaxelPertuzumabPrednisoloneTrastuzumabVinorelbineChemo-substanceAbirateroneBicalutamideCisplatinCyclophosphamideDocetaxelDoxorubicinLeuprorelinPaclitaxelPertuzumabPrednisoloneTrastuzumabVinorelbineChemo-substanceAbirateroneBicalutamideCisplatinCyclophosphamideDocetaxelDoxorubicinLeuprorelinPaclitaxelPertuzumabPrednisoloneTrastuzumabVinorelbineChemo-substanceAbirateroneBicalutamideCisplatinCyclophosphamideDocetaxelDoxorubicinLeuprorelinPaclitaxelPertuzumabPrednisoloneTrastuzumabVinorelbineNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideNo. Substances1234679Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlArthalgiaAstheniaCardiotoxicityConstipationDiarrheaEdemaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHeadacheHepatotoxicityHyperglycemiaHyperkalemiaHypertensionHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaIncrease AminotransferasesInfectionsLeukopeniaLymphopeniaMucositisNeuropathyNeutropeniaPneumonitisPruritusPyrexiaQTc Time ExtensionRashRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorAiroldi MBhattasali ODebaere DFushimi CGilbert JKurzrock RLocati LDTakahashi HDiseaseMetastasierter therapieresistenter Speicheldrüsentumor, Her2+, ECOG 0-2Speicheldrüsenkarzinom, lokal fortgeschritten oder metastasiertSpeicheldrüsentumor, Androgen-Rezeptor positiv, lokal fortgeschritten oder metastasiert, ECOG 0-2Speicheldrüsentumor, Her2+, metastasiert oder lokal fortgeschritten und nicht resektabel (T4b, N2c oder N3), ECOG 0-2Speicheldrüsentumor, lokal fortgeschritten, nach oder ohne Debulking-OPSpeicheldrüsentumor, lokal fortgeschritten oder metastasiert, Androgen-Rezeptor positiv, kastrationsresistent, ECOG 0-2Speicheldrüsentumor, lokal fortgeschritten oder metastasiert, vortherapiert, ECOG 0-2Speicheldrüsentumor: mucoepidermoides Karzinom oder Adenokarzinom, metastasiert oder rezidiviertOriginDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, TokyoDepartment of Radiation Oncology, Kaiser Permanente Medical Center, Los Angeles, CaliforniaFondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyInternational University of Health and Welfare Mita Hospital, Tokyo, JapanLouisiana State University Medical Center, New Orleans, LouisianaMoores Cancer Center, UC San Diego, San Diego, USA, MyPathway trialSan Giovanni Antica Sede Hospital, Torino, ItalyUniversity Hospitals Leuven, Catholic University Leuven, BelgiumProtocols in Revision 11 protocols foundProtocols under revision.CAP - Cisplatin 50 / Doxorubicin 50 / Cyclophosphamide 600, Salivary Gland Tumor (PID1696)Cisplatin 40 / Radiation, Salivary Gland Tumor (PID1699)Leuprorelin 3.75 / Abiraterone 1000 / Prednisolone 5, Salivary Gland Tumor (PID1956)Leuprorelin 3.75 / Bicalutamide 80, Salivary Gland Tumor (PID1700)Paclitaxel 200, Salivary Gland Tumor (PID2239)Pertuzumab 420 / Trastuzumab 6, Salivary Gland Tumor, Cycle 2+ (PID1702)Pertuzumab 840 / Trastuzumab 8, Salivary Gland Tumor, Cycle 1 (PID1701)Trastuzumab 6 / Docetaxel 70 - Trastuzumab 6 Maintenance, Salivary Gland Tumor (PID1711)Trastuzumab 6 / Docetaxel 70, Salivary Gland Tumor, Cycle 2+ (PID1698)Trastuzumab 8 / Docetaxel 70, Salivary Gland Tumor, Cycle 1 (PID1697)Vinorelbine 25 / Cisplatin 80, Salivary Gland Tumor (PID1695)
